Satya Bio Report | Updated February 2, 2026
Head-to-head comparison of clinical efficacy data across development programs (sorted by placebo-adjusted response)
| Drug | Trial | Dose | Endpoint | Result | Placebo | Δ vs Placebo | Population | Source |
|---|---|---|---|---|---|---|---|---|
| HS-20093 (GSK) | Phase 1/2 | Dose escalation | ORR | 75% | 0% | 75% ★ | All patients | WCLC 2023 |
| Ifinatamab deruxtecan (DS-7300) | Phase 1/2 | 8 mg/kg Q3W | ORR | 52% | 0% | 52% | All patients | ASCO 2024 |
★ = Best-in-class result | Purple = biomarker-selected population
Strategic positioning and key differentiators for each development program
| Drug | Strategy | Dosing | Biomarker | Half-Life | Beyond Lead Indication |
|---|---|---|---|---|---|
| Ifinatamab deruxtecan | Platform leader | 8-16 mg/kg Q3W IV | No | ~6 days | Pan-solid tumor |
| HS-20093 | Fast follower | TBD | No | TBD | Solid tumors |
| Risk | Severity | Mitigation |
|---|---|---|
| Competition from other ADC targets (TROP2, HER3, etc.) | Medium | B7-H3 expression is broader and more consistent than alternatives |
| Merck/Daiichi dominance may crowd out other players | High | Differentiation through indication focus or modality |
| Sponsor | Trials | Type |
|---|---|---|
| MacroGenics | 10 | Industry |
| UNC Lineberger Comprehensive Cancer Center | 5 | Academic |
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 4 | Industry |
| Hansoh BioMedical R&D Company | 4 | Industry |
| Peking University People's Hospital | 3 | Academic |
| St. Jude Children's Research Hospital | 3 | Academic |
| Daiichi Sankyo | 3 | Industry |
| DualityBio Inc. | 2 | Industry |
| Shenzhen Geno-Immune Medical Institute | 2 | Academic |
| Stanford University | 2 | Academic |
23 assets tracked • 4 deals worth $5.8B • 4 in Phase 3
BTD Breakthrough Therapy ODD Orphan Drug PRIME EU Priority FT Fast Track
| NCT ID | Title | Phase | Status | Sponsor | Enrollment | Start |
|---|---|---|---|---|---|---|
| NCT07181473 | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors | Phase 1 | Recruiting | Phrontline Biopharma | 200 | 2025-08-25 |
| NCT05276609 | ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors | Phase 1 | Unknown | Shanghai Hansoh Biomedical Co., Ltd | 177 | 2021-11-28 |
| NCT05914116 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Phase 1/2 | Recruiting | DualityBio Inc. | 862 | 2023-08-17 |
| NCT05562024 | TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma | Phase 1 | Recruiting | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 24 | 2022-12-30 |
| NCT04432649 | Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 | Phase 1/2 | Unknown | Shenzhen Geno-Immune Medical Institute | 100 | 2020-06-01 |
| NCT05142189 | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | Phase 1 | Recruiting | BioNTech SE | 280 | 2022-06-17 |
| NCT04670068 | Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 4 | 2021-01-27 |
| NCT06347068 | Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 42 | 2024-06-27 |
| NCT05942456 | Soluble B7-H3 as a Biomarker for Osteosarcoma | Not Applicable | Recruiting | Peking University People's Hospital | 200 | 2023-06-05 |
| NCT06018363 | Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection | Phase 1/2 | Recruiting | Dushu Lake Hospital Affiliated to Soochow University | 25 | 2023-06-01 |
| NCT06305299 | Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 27 | 2024-07-29 |
| NCT07268053 | A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases | Phase 1 | Not yet recruiting | Nader Sanai | 15 | 2026-01 |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | Terminated | MacroGenics | 67 | 2015-09 |
| NCT05064306 | 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults | Not Applicable | Unknown | Memorial Sloan Kettering Cancer Center | - | - |
| NCT05474378 | B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme | Phase 1 | Recruiting | Stanford University | 39 | 2022-07-12 |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase 1/2 | Terminated | MacroGenics | 143 | 2018-11-21 |
| NCT06052423 | ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | Withdrawn | Hansoh BioMedical R&D Company | - | 2024-11-30 |
| NCT06912152 | MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors | Phase 1 | Recruiting | Zhejiang University | 12 | 2025-05-12 |
| NCT06112704 | HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors | Phase 2 | Recruiting | Hansoh BioMedical R&D Company | 220 | 2024-02-06 |
| NCT05366179 | Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 36 | 2022-09-02 |
| NCT06778603 | B7-H3 NIR Imaging for Osteosarcoma Surgery | Phase 1/2 | Recruiting | Peking University People's Hospital | 32 | 2024-01-01 |
| NCT07099898 | A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) | Phase 3 | Recruiting | GlaxoSmithKline | 300 | 2025-08-11 |
| NCT05241392 | Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma | Phase 1 | Recruiting | Beijing Tiantan Hospital | 30 | 2022-01-27 |
| NCT05768880 | Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | Phase 1 | Recruiting | Seattle Children's Hospital | 72 | 2023-05-05 |
| NCT05515185 | B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors | Phase 1 | Unknown | The First People's Hospital of Lianyungang | 30 | 2022-09-09 |
| NCT07172958 | Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) | Phase 1 | Recruiting | Children's National Research Institute | 18 | 2026-01-27 |
| NCT03198052 | GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 30 | 2017-07-01 |
| NCT05752877 | Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma | Not Applicable | Recruiting | Second Affiliated Hospital of Soochow University | 12 | 2021-05-01 |
| NCT04842812 | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 40 | 2021-01-01 |
| NCT06646627 | Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors | Phase 1 | Recruiting | Stanford University | 48 | 2024-11-11 |
| NCT06454955 | Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors | Phase 1 | Recruiting | Peking University Cancer Hospital & Institute | 50 | 2024-01-01 |
| NCT06500819 | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors | Phase 1 | Recruiting | Crystal Mackall, MD | 41 | 2024-07-11 |
| NCT03406949 | MGD009/MGA012 Combination in Relapsed/Refractory Cancer | Phase 1 | Completed | MacroGenics | 25 | 2018-02-27 |
| NCT05835687 | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 48 | 2023-04-27 |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 540 | 2024-05-21 |
| NCT01918930 | Tissue Procurement Substudy for Participants in Study CP-MGA271-01 | Phase 1 | Terminated | MacroGenics | 6 | 2013-07 |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | Phase 1 | Recruiting | Seattle Children's Hospital | 90 | 2019-12-11 |
| NCT07222735 | Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 42 | 2025-12-05 |
| NCT06825624 | ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 560 | 2024-10-03 |
| NCT06158139 | Autologous CAR-T Cells Targeting B7-H3 in PDAC | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 27 | 2024-07-18 |
| NCT04385173 | Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma | Phase 1 | Unknown | Second Affiliated Hospital, School of Medicine, Zhejiang University | 12 | 2022-12-01 |
| NCT02982941 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | Phase 1 | Completed | MacroGenics | 25 | 2016-12 |
| NCT02381314 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | Phase 1 | Completed | MacroGenics | 24 | 2015-03-26 |
| NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Phase 1/2 | Recruiting | Radiopharm Theranostics, Ltd | 61 | 2026-02 |
| NCT06953089 | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Phase 2 | Recruiting | DualityBio Inc. | 492 | 2025-07-18 |
| NCT06372236 | UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors | Phase 1 | Completed | Peking University | 10 | 2023-12-05 |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 32 | 2022-07-06 |
| NCT05991583 | A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors | Phase 1/2 | Recruiting | SUNHO（China）BioPharmaceutical CO., Ltd. | 25 | 2023-07-03 |
| NCT05280470 | Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Recruiting | Daiichi Sankyo | 187 | 2022-03-09 |
| NCT04077866 | B7-H3 CAR-T for Recurrent or Refractory Glioblastoma | Phase 1/2 | Unknown | Second Affiliated Hospital, School of Medicine, Zhejiang University | 40 | 2023-06-01 |
Showing 50 of 72 trials. Download Excel for complete data.
| PMID | Title | Authors | Journal | Year |
|---|---|---|---|---|
| No publications found | ||||
Authors ranked by publication count from PubMed search results
| Name | Institution | Publications | First Author | Last Author | Status |
|---|---|---|---|---|---|
| No authors found in publications | |||||